<DOC>
	<DOC>NCT00415636</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer.</brief_summary>
	<brief_title>Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Has at least one lesion that can be evaluated by RECIST Has fully recovered from all toxicities due to the following: Has a life expectancy of at least 3 months. Negative serum pregnancy test. Is pregnant or breastfeeding. Is a woman of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards. Is a man of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards. Has a history of brain metastases, unless adequately treated and without radiologic evidence of progressive disease for at least 3 months after completion of therapy. Has a known active infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>